Edwards Lifesciences (EW) Operating Expenses (2009 - 2026)

Edwards Lifesciences has reported Operating Expenses for 18 years, with the latest figure at $846.4 million in Q2 2026.

• On a quarterly basis, Operating Expenses rose 6.64% year-over-year to $846.4 million in Q2 2026; TTM through Jun 2026 was $3.6 billion, a 21.0% increase from a year earlier, with the FY2025 full-year figure at $3.5 billion, up 21.06% from the prior year.
• Operating Expenses was $846.4 million for Q2 2026 at Edwards Lifesciences, up from $822.6 million in the prior quarter.
• The five-year high for Operating Expenses was $1.1 billion in Q4 2025, with the low at $325.5 million in Q4 2022.
• Average Operating Expenses over 5 years is $731.8 million, with a median of $729.3 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses slumped 49.4% in 2022, then jumped 105.41% in 2023.
• Over 5 years, Operating Expenses stood at $325.5 million in 2022, then soared by 105.41% to $668.6 million in 2023, then advanced by 15.24% to $770.5 million in 2024, then soared by 40.06% to $1.1 billion in 2025, then retreated by 21.57% to $846.4 million in 2026.
• The last three Operating Expenses figures came in at $846.4 million (Q2 2026), $822.6 million (Q1 2026), and $1.1 billion (Q4 2025), per Business Quant data.